Sanofi (SNY)

Market Cap	113.67B -17.4%
Revenue (ttm)	54.85B +5.5%
Net Income	9.17B +40.5%
EPS	7.48 +43.6%
Shares Out	1.21B
PE Ratio	12.39
Forward PE	9.49
Dividend	$1.60 (3.42%)
Ex-Dividend Date	May 9, 2025

Volume	2,227,792
Open	47.57
Previous Close	47.08
Day's Range	46.64 - 47.59
52-Week Range	43.32 - 55.73
Beta	0.32
Analysts	Buy
Price Target	58.00 (+24.04%)
Earnings Date	Apr 23, 2026

About SNY

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for onc...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1994
• Employees: 74,846
• Stock Exchange: NASDAQ
• Ticker Symbol: SNY
• Website: https://www.sanofi.com

Financial Performance

In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for SNY stock is "Buy." The 12-month stock price target is $58.0, which is an increase of 24.04% from the latest price.

Price Target

$58.0

(24.04% upside)

Analyst Consensus: Buy